What does an Invokana lawsuit look like?
Like many other pharmaceutical cases, a lawsuit against the manufacturers or marketers of Invokana, such as Janssen Pharmaceuticals Inc. or Johnson & Johnson, would fall under the rubric of products liability. More than likely, it would probably include a failure to warn allegation. What this means is that its makers or distributors should have warned prospective users about its risks and side effects so that they could have made an informed decision about using Invokana or another alternative. Here is a list of all the elements a successful failure-to-warn case must include:
- You used Invokana.
- You were injured after taking Invokana.
- You were not warned about the potential risks of taking Invokana.
- The lack of warnings caused your injuries.
Because a failure to warn case involves strict liability, all those involved in the creation and sale of Invokana are liable to you if you are injured after taking it. This includes the manufacturers, marketers, distributers, sales agents, affiliated laboratories, pharmacies, and medical providers. One exception to the strict liability imposed upon manufacturers in failure to warn cases is when they inform doctors about the potential risks involved with Invokana and other medications. This is called the “learned intermediary” exception. It states that manufacturers relieve their responsibility to warn patients when they adequately inform their doctors about the risks involved with the drug prescribed. They are relieved from any liability even if the drug’s warning does not sufficiently warn the patient about the same risks.
The other products liability argument that might emanate from an Invokana dispute is that it was defectively designed. Here are all of its elements:
- Invokana is defectively designed.
- You took Invokana as it was intended to be taken.
- You were injured as a result of taking Invokana.
- Invokana’s defective design caused your injuries.
What this suit essentially alleges is that it should have been made differently. Like failure-to-warn cases, all those involved from inception to sale are implicated because it is a strict liability case. Of course, this is no small undertaking. Pharmaceutical companies spend millions of dollars and many years developing these products so overcoming their argument that they are adequately designed is extremely hard. This is why failure to warn cases are much more common than defective design cases against drug companies.
For additional information see the following pages: